Outcome MeasureQuality of Life

QLES-Q-SF

Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form

2 Papers in Blossom

Outcome Data Across Studies

Reported results for QLES-Q-SF across 2 studies with quantitative data.

Outcome data across 6 study arm–timepoint observations
SD
Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes
2024Secondary
Psilocybin(experimental)01542.97.6—
Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes
2024Secondary
Psilocybin(experimental)211559.211.6—
Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes
2024Secondary
Psilocybin(experimental)841563.313.6—
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
2025Secondary
Psilocybin(experimental)01238.37.9—
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
2025Secondary
Psilocybin(experimental)211249.2——
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
2025Secondary
Psilocybin(experimental)841251.3——

Papers Using QLES-Q-SF

Open Accessindividual

Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial

This open-label trial (n=12) conducted at Sheppard Pratt Hospital finds that psilocybin (25mg) significantly decreases depressive symptoms in patients with severe treatment-resistant depression (TRD) at 3 weeks (MADRS −15.8) and 12 weeks (MADRS −17.2) post-treatment. Exploratory analyses suggest the Oceanic Boundlessness dimension correlates with antidepressant responses, while patients with comorbid PTSD show reduced antidepressant effects.

Published
Journal
American Journal of Psychiatry
Authors
Aaronson, S. T., Van Der Vaart, A., Miller, T., Lapratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Suppes, T., Sackeim, H. A.
Open Accessindividual

Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes

In an open‑label, non‑randomised 12‑week trial of 15 patients with treatment‑resistant bipolar II depression, a single 25 mg dose of synthetic psilocybin plus psychotherapy produced large, rapid and sustained reductions in depressive symptoms (mean MADRS change −24 points at 3 weeks; 12/15 responders, 11/15 remissions) without significant increases in mania or suicidality. These preliminary results suggest psilocybin may be an effective and safe acute treatment for bipolar II depression and merit confirmation in larger randomised controlled trials.

Published
Journal
JAMA Psychiatry
Authors
Aaronson, S. T., van der Vaart, A., Miller, T., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Sackeim, H. A., Suppes, T.

Quick Facts

Full Name
Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form
Domain
Quality of Life
Papers Indexed
2
Score Range
14–70
Interpretation
Higher = better
All Measures